| |
Choosing the right partner to deliver decentralised clinical trials is crucial. ICON has the experience and expertise to overcome the challenges in patient recruitment and retention to deliver study success. Explore ICON's DCT capabilities. 
|
|
Today’s Big NewsOct 6, 2023 |
|
October 16-18, 2023 | Boston, MA This event is designed to bring together leaders and executives within the biotech and life sciences industry to discuss the most pressing challenges around product development, bringing an asset to market and building successful companies in this complex landscape. LAST CHANCE TO REGISTER! 
|
|
| By James Waldron Outside of a global pandemic, it’s rare for a medicine to truly become a household name. But Novo Nordisk’s Wegovy is rapidly reaching that status, with the obesity drug accruing more front pages and celebrity endorsers every day. |
|
|
|
By Max Bayer Atsena Therapeutics has cut staff to funnel more money toward an inherited retinal disease program that just began dosing for a phase 1/2 trial in August. |
By Max Bayer,Gabrielle Masson With Eli Lilly on the precipice of one of its most consequential FDA approvals ever, the company is making major executive moves. |
By Ayla Ellison In this episode of "The Top Line," we delve into the uncharted territory that pharma marketers face, from harnessing AI's potential to navigating the Inflation Reduction Act. |
By Nick Paul Taylor Bristol Myers Squibb is putting Paradigm’s plans to rebuild the clinical trial system to the test, teaming up with the startup to design studies that can activate community health provider organizations as sites. |
By Angus Liu Amgen has completed its $27.8 billion acquisition of Horizon Therapeutics after fending off a legal challenge by the U.S. antitrust watchdog. |
By Fraiser Kansteiner Judgment Day has come for Amgen’s first-in-class KRAS inhibitor Lumakras as the FDA’s Oncologic Drugs Advisory Committee gathered Thursday to weigh the merits of the cancer med’s phase 3 clinical trial CodeBreak 200. |
By Conor Hale The Library of Congress has recently become a battleground over the right to repair, including for high-tech imaging machines and surgical robots. |
By Angus Liu Takeda will withdraw lung cancer drug Exkivity after a confirmatory trial failure. Kyowa Kirin is buying gene therapy biotech Orchard Therapeutics. Biogen's biosimilar version of Roche's Actemra, bought from Bio-Thera Solutions, won an FDA nod. And more. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," we delve into the uncharted territory that pharma marketers face, from harnessing AI's potential to navigating the Inflation Reduction Act. |
|
|---|
|
|
|
October 16-17 | Boston, MA LAST CHANCE! Enhance commercial success by optimizing the pipeline and making prioritization decisions. Don't miss this one of a kind event, Register today! 
|
|
Webinar Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
eBook Learn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
Whitepaper Economic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
Whitepaper From Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Whitepaper Learn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
| |
|
